Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

The WHO has classed this outbreak as “extraordinary” due to the lack of therapeutic options and epidemiological trends.

ITALVACUUM will participate in EXPOQUIMIA 2026, taking place in Barcelona from 2 to 5 June, where the company will present its vacuum drying technologies developed for pharmaceutical and ...

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.

Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.